What does this research mean for the field?

Breath aldehyde profiling using PFBHA-GC/MS does not effectively differentiate prostate cancer from control subjects due to low analyte detection rates and minimal between-group contrasts. Novelty: ClaimNovelty.CONFIRMATORY. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

The research aims to evaluate the effectiveness of breath aldehyde profiling using PFBHA-GC/MS as a biomarker for prostate cancer.

March 10, 2026Open Access

Breath Aldehyde Profiling using PFBHA-GC/MS as a Prostate Cancer Biomarker

Key Points

The research aims to evaluate the effectiveness of breath aldehyde profiling using PFBHA-GC/MS as a biomarker for prostate cancer.
Single-compound aldehyde profiling conducted using PFBHA-GC/MS
Comparison between prostate cancer cases and control group
Assessment of analyte detection rates and between-group contrasts
No significant differentiation found between prostate cancer and control groups
Low analyte detection rates hindered conclusive results
Recommendations include enhanced sensitivity methods like GC×GC-HRMS

Abstract

Single-compound aldehyde profiling with PFBHA-GC/MS failed to differentiate PCa from controls, primarily due to low analyte detection rates and minimal between-group contrasts. Enhanced-sensitivity platforms (e.g., GC×GC-HRMS or MEMS-based pre-concentrators) and multi-component VOC signatures coupled with rigorous control of smoking and ambient confounders are needed before breath testing can contribute meaningfully to prostate cancer screening.

Bookmark

View Full Paper

Cite This Study

Sasaki et al. (Sun,) studied this question.

synapsesocial.com/papers/69af94da70916d39fea4bc62 https://doi.org/https://doi.org/10.31557/apjcp.2026.27.3.779

Bookmark

View Full Paper